⚡ Interrogation des APIs scientifiques en cours…
⚡ Interrogation des APIs scientifiques en cours…
Authors' conclusion
Does not affect the score
Publi-Score
Fidelity
Abstract (PubMed)
Prospective multicenter analysis of 177 patients with metastatic breast cancer showing that patients with ≥5 circulating tumor cells per 7.5 ml blood had shorter progression-free survival (2.7 vs 7.0 months) and overall survival (10.1 vs >18 months). Cell counts remained significant predictors after treatment initiation and were the strongest independent prognostic variables.
Coeff. authors = avg(0.65, 1.00) = 0.83
Coeff. editorial = avg(1.00, 0.90) = 0.95
min(0.83, 0.95) = 0.83← lowest dominates
Final coefficient : 0.83
Final score = 42.3/52.8 × 0.83 × 100 = 66/100
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson M — 2017 · The New England Journal of Medicine
Contrasted results5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally adva…
Gianni L — 2016 · The Lancet Oncology
Overdiagnosis in cancer.
Welch HG — 2010 · Journal of the National Cancer Institute
The benefits and harms of breast cancer screening: an independent review.
Marmot MG — 2012 · Lancet (London, England)
Efficacy of bilateral prophylactic mastectomy in women with a family history of breast …
Hartmann LC — 1999 · The New England journal of medicine